David Wood is a Cardiology physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1819 Clinch Avenue
Suite 108
Knoxville, TN 379162435
Telephone
865-546-5111Provider last certified this registry record 18 Jun 2020.
Clinical trials
- European Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease (EUROASPIRE VI)
Sponsor: European Society of Cardiology
- MANTA Ultrasound Closure Study
Sponsor: Essential Medical, Inc.
- Standardized Invasive Hemodynamics for Elevated Gradients Post TAVR (DISCORDANCE TAVR)
Sponsor: University of British Columbia
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABIOMEDProgram year20251 payment
- Boston Scientific CorporationProgram year20253 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
76.3%Beta blocker20.2%Metoprolol Succinate27%Carvedilol26%Sotalol15%Metoprolol Tartrate13%Atenolol6%Bisoprolol Fumarate5%Nebivolol Hcl4%Labetalol Hcl2%Propranolol Hcl2%Part D<11 patientsStatin11.2%Atorvastatin Calcium65%Rosuvastatin Calcium31%Pravastatin Sodium5%Part D<11 patients+ 14 more classes in this area
Blood & clotting
18.7%P2Y12 inhibitor9.5%Clopidogrel71%Brilinta19%Prasugrel Hcl11%Part D<11 patientsFactor Xa inhibitor9.2%Eliquis72%Xarelto28%Part D≥54 patientsMetabolism & gastrointestinal
4.5%SGLT2 inhibitor3.7%Jardiance58%Farxiga42%Part D≥17 patientsPotassium supplement0.4%Potassium Chloride100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”